SGLT2 inhibition restrains thyroid cancer growth via G1/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways

BACKGROUND: Although the prognosis for most patients with papillary thyroid cancer (PTC) is good, the present treatment is ineffective for 5–10% patients. Several studies found sodium–glucose cotransporter 2 (SGLT2) inhibitors may inhibit the growth of tumors. However, whether SGLT2 inhibitors have...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yan, Yang, Longyan, Mao, Lin, Zhang, Lijie, Zhu, Yingjun, Xu, Yongsong, Cheng, Yanan, Sun, Rongxin, Zhang, Yuanyuan, Ke, Jing, Zhao, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840070/
https://www.ncbi.nlm.nih.gov/pubmed/35148777
http://dx.doi.org/10.1186/s12935-022-02496-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840070/
https://www.ncbi.nlm.nih.gov/pubmed/35148777
http://dx.doi.org/10.1186/s12935-022-02496-z

Ejemplares similares